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Abstract
Malignant mesothelioma is doubtless the more known pleural
tumour. However, according to the morphology code of the
International Classification of Diseases for Oncology (ICD-
O), there are several histological types of pleural neoplasms,
divided into mesothelial, mesenchymal and lymphoprolifera-
tive tumours, that may be misdiagnosed. In this paper we
summarise and illustrate the incidence aspects and the clinical,
pathological and radiological features of these neoplasms.
Teaching Points
• According to the ICD-O, there are 11 different histological
types of pleural neoplasm.
• Imaging, clinical and histopathological aspects of these neo-
plasms may be overlapping.
• Knowledge of different pleural tumours plays an important
role for diagnosis orientation.
Keywords Pleural neoplasm .Malignant mesothelioma .
Synovial sarcoma . Solitary fibrous tumour . Primary effusion
lymphoma
Introduction
Pleural anatomy
The two lungs and the pleurae are located in the chest. The
pleurae are thin, shimmering serous membranes. From a his-
tological point of view, each pleura is composed of a mono-
layer of mesothelial cells. These mesothelial cells rest on a
matrix of collagen, elastic fibres, blood vessels and lym-
phatics, allowing the lung and chest to expand and contract
[1]. With a rich blood supply and lymphatic system just deep
to the mesothelial layer, the pleura forms a dynamic structure
protecting the lung from infection while transmitting the
forces of respiration without damage to the underlying lung
parenchyma. The pleura consists in two sheets: one that
covers the thoracic wall and diaphragm, known as the parietal
pleura (Fig. 1) and the other called the visceral pleura covering
lungs and fissures. Surfaces of the two sheets slide smoothly
against each other during respiration. The contact between the
parietal and visceral pleurae depends on the atmospheric pres-
sure on the outside of the chest wall and inside the alveoli.
Between these layers there is a thin space known as the pleural
cavity that contains a small amount of pleural fluid (a few
millilitres in a normal human) [2]. The two sheets tend to be
separated by the elasticity of the thoracic wall (outward) and
the lungs (lengthen by inspiration). Pleura has its own nerves,
arteries and lymphatic drainage. The visceral pleura covering
the lung itself receive their innervation from the autonomic
nervous system and have no sensory innervation. Only the
parietal pleurae are sensitive to pain. Parietal pleura consists
of three regions: costal, mediastinic and diaphragmatic
(Fig. 1). In the anterior region, the mediastinal pleura turns
onto the mediastinum and covers the costomediastinal recess.
In the lower regions, the costal pleura becomes the diaphrag-
matic pleura. The anterior borders of the right and left pleurae
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meet at or close to the median axis determining the origin of
mediastinal lines at chest X-ray. At the bottom of the lung,
mediastinal pleura goes laterally, circumscribing the anatom-
ical structures at the root and continuing in the visceral pleura.
Mediastinal pleura is adherent to the pericardium, except
where the phrenic nerve descends between them. On top of
the aortic arch, the right and left pleurae approach each other
behind the oesophagus. The diaphragmatic pleura covers most
of the diaphragm. The diaphragmatic cupola is the continua-
tion of the costal and mediastinal portions of the pleura and
gains strength by a thickening of the endothoracic fascia
(subpleural membrane), attached to interior part of the first
rib and the transverse process of the seventh cervical body.
Malignant pleural mesothelioma (MM) is doubtless the
more common pleural tumour, with a characteristic poor prog-
nosis. However, according to the morphology code of the
International Classification of Diseases for Oncology, the
histotypes of pleural neoplasms can be divided into mesothe-
lial, mesenchymal and lymphoproliferative tumours
(summarised in Table 1). It is important to know that there
are tumoural histotypes other than MM because of the differ-
ent behaviour, treatment and prognosis of each neoplasm. For
the radiologist, such as for the clinician and sometimes also for
the pathologist, it can be very challenging and often impossi-
ble to distinguish among the different histotypes of pleural
tumours, that may present the same symptoms, signs, histo-
logical and radiological aspects. For these reasons, to achieve
a precise diagnosis, therapy and prognosis, it is important to
consider clinical, radiological, histopathological and immuno-
histochemical findings.
Diffuse malignant mesothelioma
DiffuseMM is a malignant neoplasm arising frommesothelial
cells in the pleura, and shows a typical growth along the pleu-
ral surfaces; less common is the malignant mesothelioma of
the pericardium and peritoneum. It is the most common pri-
mary malignancy of the pleura [3].
Up 10,000 mesotheliomas are estimated to occur annually
across the population of western Europe, Scandinavia, North
America, Japan and Australia [4], while precise registrations
are not available in areas that still use asbestos (Eastern Eu-
rope, South America, Africa and the rest of Asia, including
China. Incidence in Europe ranges by country: in the UK, the
nation with the high incidence in the area, the mean annual
number of cases is 4.1/100,000 (from 2.9 in Wales to 4.1 in
England), while Italy has 2.47/100,000. In comparison, in the
US, according to National Cancer Institute records from 1975
to 2010, there is an average of 1.0 new case of asbestos cancer
per 100,000 [5].
The most common symptoms of diffuseMM are represent-
ed by dyspnoea, usually caused by discreet pleural effusion,
chest pain, cough and weight loss. Unusual signs and symp-
toms of MM include spontaneous pneumothorax, laryngeal
Fig. 1 Schematic diagram of the
pleurae and upper airways
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nerve palsy and superior vena cava obstruction, due to medi-
astinal invasion of the neoplasm [6].
From a histopathological point of view there are four main
histotypes of diffuse MM, represented by epithelioid,
sarcomatoid, desmoplastic and biphasic MM.
Epithelioid MM shows a wide range of morphological pat-
terns, which frequently coexist in the same tumour. A tubular
histological architecture may be seen, as a papillary or
microglandular histological architecture, with more or less
connective tissue. Sometimes psammomatous bodies and ker-
atin are observed, which are useful clues in the differential
diagnosis among large cell lymphoma, metastatic malignant
melanoma and pleural epithelioid haemangioendothelioma.
Sarcomatoid MM is similar to a fibrosarcoma, but some
areas may also resemble osteosarcoma, chondrosarcoma and
other sarcomas. For these reasons it can be very difficult to
distinguish between sarcomatoid MM and sarcomas or also
sarcomatoid-type carcinomas involving the pleura, such as the
pleomorphic carcinoma of the lung or the sarcomatoid renal
cell carcinoma.
Desmoplastic MM is characterised by dense collagenised
tissue with scattered atypical cells, which may be observed in
at least 50 % of the tumour, and it may be misdiagnosed even
at histology, being confused with benign organising pleurisy.
Biphasic MM is characterised by a combination of
sarcomatoid and epithelioid pattern in about 30 % of cases.
MM prognosis is always poor, with a mean survival time of
1 year from the time of diagnosis. Negative prognostic factors
are represented by mediastinal lymph node metastasis, thorac-
ic wall and extra-pleural structure involvement, and distant
metastases [7]. The histological subtype is also related to
prognosis since the epithelioid histotype presents the best sur-
vival time, while the sarcomatoid histotype presents the worst
prognosis, whereas mixed histotypes show intermediate sur-
vival time. According to the 7th AJCC Cancer Staging Man-
ual, all the MM histological histotypes follow the same TNM
staging system, as summarised in Tables 2 and 3 [8].
On chest radiography,MMmay appear as unilateral pleural
effusion, diffuse or focal pleural thickening or as a real pleural
solid lesion. The homolateral lung may be reduced in volume,
with elevation of the diaphragm, narrowing of the intercostal
spaces and homolateral deviation of the mediastinal axis.
Computed tomography (CT) provides more accurate de-
tails regarding MM extension, in particular at the level of the
chest wall, diaphragm and pericardium, and allows a good
evaluation of extra-pleural fat planes, invasion of intercostal
muscles and bone erosions (Fig. 2). CT better recognises the
pleural thickening, in particular along the fissures that can be
so extended to simulate a Brind-like appearance^ due to the
encasement of the lung [9]. The involvement of mediastinal
structures, such as the heart, oesophagus and trachea, or the
extra-thoracic spread with involvement of the retroperitoneal
space and the liver is more uncommon and typical of extreme-
ly advanced cases [6, 10].
Furthermore, CT allows a better evaluation of the hilar and
mediastinal lymph nodes and clearly depicts pulmonary
metastasis.
CT is essential in MM staging, but it is not very accurate in
the evaluation of the early invasion of the structures of the
thoracic wall, such as the endothoracic fascia and the intercos-
tal muscles, which leads sometimes to the underestimation of
chest wall involvement. Magnetic resonance (MR) imaging,
thanks to its high contrast and spatial resolution, allows better
assessment of the tumour spread than CT, in particular
concerning the invasion of the diaphragm and endothoracic
fascia, being very useful in those patients with potentially
resectable MM (Fig. 3) [11]. Recent MRI studies have also
suggested that the apparent diffusion coefficient (ADC) of the
epithelioid subtype of MM is higher than the ADC of the
sarcomatoid subtype, a difference that may be a surrogate
imaging biomarker [12]. Coolen et al. [13] have suggested
the usefulness in diagnosis and guide-for-biopsy of a new
MRI sign in diffusion-weighted imaging called ‘pleural poin-
tillism’, defined as multiple (minimum of two) hyperintense
areas visible by using a b value of 1,000 in the pleura not
identifiable with lower b values.
Neovascularisation has been shown to be necessary for
tumour growth [14] and many studies have confirmed the
negative prognosis in highly vascularised MM. Giesel et al.
[15] showed that parametric images based on dynamic
Table 1 WHO histological classification of tumours of the pleura, according to the ICD-O
MESOTHELIALTUMOURS LYMPHOPROLIFERATIVE DISORDERS MESENCHYMALTUMOURS
1- Diffuse malignant mesothelioma (MM)
• Epithelioid mesothelioma
• Sarcomatoid mesothelioma
• Desmoplastic mesothelioma
• Biphasic mesothelioma
2- Localised malignant mesothelioma
3- Well-differentiated papillary mesothelioma
4- Adenomatoid tumour
5- Primary effusion lymphoma
6- Pyothorax-associated lymphoma
7- Epithelioid haemangioendothelioma
• Angiosarcoma
8- Synovial sarcoma
• Monophasic
• Biphasic
9- Solitary fibrous tumour of the pleura
10- Calcifying tumour of the pleura
11- Desmoplastic round cell tumour
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contrast-enhanced (DCE) MR imaging of MM depicts not
only the lesion and its extent but also the heterogeneity in
intratumoural vascularisation in MM. The pharmacokinetic
parameters may represent predictors of the therapeutic
response.
Positron emission tomography (PET) with 2-[fluorine-18]-
fluoro-2-deoxy-D-glucose (FDG) can help in the diagnosis
and staging of MM, by using the high standardised uptake
value (SUV), which is significantly higher in MM than in
benign pleural thickening. In fact, not all the pleural thicken-
ings contain necessarily neoplastic cells, and for this reason
PETcan guide the chest biopsy, indicating the most FDG-avid
tumoural regions. Figures 4, 5, 6, 7 and 8 show some typical
aspects of MM staging [16].
Based on the data reported in the literature, this combined
modality is also useful in the evaluation of therapeutic out-
come and post-treatment surveillance for recurrence, progno-
sis based upon the intensity of FDG uptake [17].
Ultrasound should also have a role in MM diagnosis. US
can be used to guide biopsy to the thickened pleura in MM
with pleural effusion. MM presenting without effusion, how-
ever, is more of a diagnostic challenge [18]. The therapy is
based on surgery (aggressive surgical resection), associated
with radiotherapy and chemotherapy, in different protocols
[6] However, even with more aggressive and complex thera-
peutic protocols, the mean survival time hardly reaches
24 months [19, 20].
A relevant topic about MM is the differential diagnosis
with pleural plaques, which are relatively common lesions
formed by deposits of hyalinised collagen fibres in the parietal
pleura. They are indicative of asbestos exposure and typically
become visible 20 or more years after the inhalation of asbes-
tos fibres. Differently from MM, pleural plaques usually do
not infiltrate adjacent structures and the thoracic wall and are
less frequently associated with pleural effusion than MM.
Synovial sarcoma
Synovial sarcoma is a rare mesenchymal tumour (10 % of all
soft tissue sarcomas), usually located in the lower and upper
extremities, but in some infrequent cases it arises also within
thoracic structures, such as the heart, mediastinum, chest wall,
lung and pleura. Synovial sarcoma is thought to originate from
primitive (uncommitted) mesenchymal cells that undergo
Table 2 TNM classification of MM, according to the 7th AJCC Cancer Staging Manual
T (sum of the extent of spread of the primary tumour)
TXa The main tumour cannot be assessed for some reason
T0a No evidence of a main tumour
T1a MMT involvement of the pleura on one side of the chest (even the diaphragmatic or mediastinal pleura)
T2a T1+involvement of chest wall, diaphragmatic and mediastinal pleura and at least one of diaphragm or
lung infiltration
T3a T2+infiltration of at least one of the following: endothoracic fascia, fatty mediastinal tissue, a SINGLE
place in the deeper
layers of the chest wall, surface of the pericardium
T4b T3+infiltration of at least one of the following: more than one place in the deeper layers of the chest wall,
the peritoneum, any organs in the mediastinum, the spine, the other side of the chest, the heart muscle
N (regional lymph nodes involvement)
NX The nearby lymph nodes cannot be assessed
N0 No spread to the nearby lymph nodes
N1 Spread to the hilar or bronchial lymph nodes on the same side as the primary tumour
N2 Spread to other lymph nodes on the same side as the primary tumour (subcarinal, mediastinal, internal
mammary and peridiaphragmatic)
N3 Spread to the supraclavicular lymph nodes and/or to those on the opposite side to the primary tumour
M (primary tumour spread to the other organs of the body)
M0 No spread to distant organs or areas
M1 Spread to distant sites (lymph nodes and organs)
aMMT may still possibly be surgically removed
bMMT has grown too far to be completely surgically removed
Table 3 Stage grouping for MM, according to the 7th AJCC Cancer
Staging Manual
Stage I T1, N0, M0
Stage II T2, N0, M0
Stage III T1/T2, N1/N2, M0 or T3, N0-N2, M0
Stage IV T4, any N, M0 or any T, N3, M0 or any T, any N, M1
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differentiation to resemble synovial cells. This belief is con-
sistent with the malignancy of mesenchymal cells that under-
go differentiation to resemble synovial cells [21]
It is more frequent in young patients (average age of
25 years), with males and females affected equally. A precise
aetiological factor is not known; however, in all cases a spe-
cific chromosomal translocation t(X;18)(p11.2;q11.2) is
found [22, 23]. At gross pathology the synovial sarcoma ap-
pears as a localised solid tumour, usually arising in the visceral
pleura, with very large dimensions (up to 20 cm). Synovial
sarcoma often presents cystic areas mixed with necrotic areas,
and some of those tumours may also present a pseudocapsule,
due to the compression of adjacent compressed lung tissue,
with packed blood vessels and granulation tissue [24]
A typical histological feature is represented by a biphasic
aspect, with epithelial and spindle cells components, but sy-
novial sarcoma may present also as monophasic neoplasm
with exclusively spindle cell component. Both histotypes
can be confused with an MM, although synovial sarcoma
usually affects younger patients, presents a more localised
aspect, grows faster and often presents a pseudocapsule,
which is typically absent in the MM [25, 26].
On chest radiography, the chest synovial sarcoma usually
appears as a homogeneous round lesion, with well-defined
margins, sometimes lobulated, without cavitation, calcifica-
tion or lymphadenopathy. Calcifications are frequently
depicted (up to 30 %) [27].
On CT images, synovial sarcoma appears as a well-defined
mass, homogeneous on direct CT, with an irregular enhance-
ment after contrast injection, with some hypodense areas, cor-
responding with necrotic or haemorrhagic spots. In most
cases, a thin peripheral rim of enhancement, corresponding
to the pseudocapsule, may be identified. Sometimes consen-
sual pleural effusion is also reported. It is also very hard to
a bFig. 2 Sarcomatoid
mesothelioma; axial view
contrast-enhanced CT scan: soft
tissue (a) and bones (b) window
images showing a large thoracic
wall mass with inhomogeneous
enhancement, involving the
lateral arch of a rib, that appears
eroded (white arrow), a typical
infiltration sign
a b cFig. 3 Biphasic mesothelioma;
chest X-ray film (a) showing a
right basal and lateral pleural
thickening with fissure
involvement (thick arrow). Lung
MR confirm these findings, both
on fat saturation T1-weighted
image (b) and spin echo T2-
weighted sequence (c) that better
demonstrates a mild basal anterior
pleural effusion (arrowhead)
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distinguish between a primary thoracic synovial sarcoma and
a synovial sarcoma metastatic to the pleura, because both
forms have almost the same features.
The extra-pleural synovial sarcoma often shows a destruc-
tion of the cortical bone, intratumoural calcifications and in-
filtration of the adjacent muscular structures. In primary pleu-
ral synovial sarcoma, sclerotic reaction of the ribs adjacent to
the tumour is observed, without a real lysis of the cortical bone
or invasion of the adjacent chest wall structures (Fig. 9).
MRI can depict tumoural nodular soft tissue and
multilocular fluid filled components, T1-weighted images
typically show a predominantly heterogeneous multilobulated
soft-tissue mass with signal intensity similar to or slightly
higher than that of muscle. T2-weighted images show prom-
inent heterogeneity [28], with nodular areas of intermediate
signal intensity mixed with hyperintense areas (cystic, necrot-
ic, haemorrhagic or mixoid material) [29]. After intravenous
contrast media injection, a prominent heterogeneous enhance-
ment may be identified. The administration of gadolinium-
based agents is important also to characterise synovial sarco-
mas with predominantly cystic characteristics [26].
The therapy is primarily based on surgical resection with
chemo and radiation therapy. Mean survival time at 5 years is
50-80 %. Worst prognostic factors are the tumour dimensions
(more than 5 cm), a non-radical surgical resection, and the
presence of distant metastasis.
Solitary fibrous tumour
Solitary fibrous tumour is another rare pleural neoplasm,
representing less than 5 % of all tumours involving the pleura,
with no correlation with asbestos exposure. Solitary fibrous
tumour has a mass-like form arising both from the visceral and
parietal pleura, and more than 50 % of cases show a vascular
pedicle.
From the hystopathological point of view solitary fibrous
tumours are characterised by both hypocellular and
hypercellular areas, and those areas are sustained by a
haemangiopericytoma-like fibrovascular stroma. This feature
is common also in other fibrous tumours of other tissues.
Common symptoms are cough, chest pain and dyspnoea,
even though many patients are asymptomatic, and the solitary
fibrous tumour represents an occasional finding. An uncom-
mon sign is hypertrophic osteoarthropathy. A sporadic but
pathognomonic sign is the symptomatic hypoglycaemia, due
a bFig. 4 Stage I of MM; contrast-
enhanced CT scan: coronal (a)
and axial (b) view. Diffuse
circumferential thickening of the
thoracic, mediastinal and
diaphragmatic pleura involving
even the fissure. No extra-pleural
infiltration or significant
lymphadenopaties are observed
(only two small lymph nodes are
reported—white arrows)
Fig. 5 Stage II of MM; contrast-enhanced CT scan: coronal view. Focal
pleural enhancing thickening that infiltrates the left hemidiaphragm (thick
arrow)
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to the production of an insulin-like growth factor by the
tumour [30].
On chest radiography a solitary fibrous tumour appears as a
homogeneous round mass, with smooth and well-defined
margins (Fig. 10). Erosions of adjacent bone structures are
extremely rare. Tumours presenting the vascular pedunculus
may change in shape and position during breathing and
decubitus. Usually the mass forms obtuse angles with the
pleural surface on chest radiography, but in the case of large
masses, not so infrequent, they form also acute angles. In
some cases it can be noticed also a mild homolateral pleural
effusion [31].
On unenhanced CT, the solitary fibrous tumour usually
appears slightly hypodense, with a slight and homogeneous
enhancement after iodinated contrast medium injection
in small lesions which may become heterogeneous, in
large or giant tumours, due to the presence of necrosis,
haemorrhage, mixoid and cystic areas (in 7 % of cases
calcifications may be seen). Another peculiarity of soli-
tary fibrous tumour is represented by the compression
determined by the large tumoural mass on adjacent lung
and mediastinum, rather than by a real infiltration of
these structures. Usually there are no locoregional
lymphadenopathies (Fig. 11).
The therapy is based on the surgical excision, and the
prognosis is good in the majority of patients. However
solitary fibrous tumours present a significant incidence
of recurrence, and for this reason an aggressive surgical
strategy should always be preferred. Malignant solitary
fibrous tumours, with a high rate of recurrence and me-
tastasis, have been reported [30].
a b
Fig. 6 Stage III of MM. Contrast-enhanced CT scan: coronal (a) and
axial (b) view show a severe left lung hypoexpansion, with
circumferential irregular pleural thickening and fissure thickening
(white arrow); left hilar inhomogeneous pathological lymph node may
be seen (thick arrow), and infiltration of the left hemidiaphragm is
reported (arrowhead); this MM (sarcomatoid mesothelioma variant) is
classified as T2, N1, M0
Fig. 7 Stage III of MM; contrast-enhanced CT scan: axial view showing
a circumferential pleural thickening, involving the mediastinal pleura and
the pericardium (white arrow), classified as T3, N0, M0
Fig. 8 Stage IV of MM; abdominal contrast-enhanced CT scan.
Aggressive MM grown through the diaphragm. An axial view
demonstrates the infiltration of the peritoneum and the liver (classified
as T4)
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Primary effusion lymphoma
Primary effusion lymphoma is a large B-cell lymphoma pre-
senting as an important serous pleural effusion, usually with-
out a real detectable mass. It typically involves the peritoneal,
pericardial and pleural cavity.
There is a strong correlation between primary effusion lym-
phoma and human herpes virus 8 (HHV8)/Kaposi sarcoma
herpes virus (KSHV). The virus is often found inside the tu-
mour cells. Usually the patients affected by the primary effu-
sion lymphoma are immunocompromised, in particular HIV
positive patients, but also transplanted and elderly patients. In
some rare cases the primary effusion lymphoma is associated
with multicentric Castelman disease (lymph node benign
hamartoma). Both forms are characterised by a high ex-
pression of viral interleukin 6 (vIL6), although a sure
a bFig. 9 Large left thoracic wall
sarcoma; contrast-enhanced CT
scan: coronal (a) and axial (b)
view. Severe left hemithorax
hypoexpansion, homolateral
hemidiaphragm superelevation
and presence of a large
polylobulated mass, with faint
enhancement and extraparietal
extension. No precise fat plane
may be seen between the
mediastinal pleura and the
pericardium (white arrow), a
finding that is highly suspicious
for mediastinal infiltration
Fig. 10 An accidental case of
solitary fibrous tumour in a 56-
year-old man: standard chest
radiography (a, b) demonstrates a
well-defined, ovalar shaped chest
wall mass. Contrast-enhanced CT,
axial plane before (c) and after (d)
contrast media administration
showing a bulky, homogeneus
and non-enhancing mass of the
left posterior chest wall
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close connection between the two forms has not yet been
established [32]
If primary effusion lymphoma is suspected, a pleural biop-
sy is necessary. The specimen may show neoplastic cells ad-
herent to the pleural surface, often surrounded by fibrin, and
sometimes showing infiltrative aspects. The primary effusion
lymphoma must be distinguished from another lymphoprolif-
erative disease of the pleura that is the pyothorax-associated
lymphoma. As it will be described subsequently, pyothorax-
associated lymphoma usually presents as a pleural mass, pos-
itive for Epstein-Barr virus (EBV) and negative for
HHV8/KSHV [33].
Typical clinical features of primary effusion lymphoma are
the presence of pleural effusion and the absence of lymphade-
nopathy, and liver or spleen enlargement [34].
CT identifies pleural effusion, usually monolateral that may
be associated with loss of volume of the involved hemithorax,
pleural thickening and the absence of pathological lymph
nodes (Fig. 12) [35].
Primary effusion lymphoma is an extremely aggressive
disease, with a very poor prognosis (less than a year of mean
survival time). The best care is based on several cycles of
chemotherapy and antiviral therapy that together seem to
show the best prolonged survival.
Pyothorax-associated lymphoma
Pyothorax-associated lymphoma is another type of large B-
cell lymphoma but, unlike primary effusion lymphoma, it pre-
sents usually as a real pleural mass. The neoplastic cells are
EBV-RNA positive and, as previously said, HHV8/KSHV
negative [36].
Usually pyothorax-associated lymphoma arises in patients
with a history of chronic pyothorax, typically resulting from
iatrogenic pneumothorax for pulmonary tuberculosis or, more
rarely, tubercular pleurisy.
Common symptoms are a consequence of the neoplastic
mass compression or infiltration of surrounding structures,
like chest or back pain, productive cough, fever, dyspnoea,
weight loss and dysphagia in case of involvement of the me-
diastinum. Frequently there is also pleural effusion. In many
patients high levels of serum lactate dehydrogenase (LDH)
may be observed [37].
On CT, a pleural mass is identified, often with a
large dimension showing invasion of the adjacent struc-
tures, in particular the thoracic wall, the lung and some-
times the mediastinum. A mild pleural effusion and
some pleural calcification may be associated. For this
reason it is always important to associate clinical and
laboratory data to propose a correct differential diagno-
sis among pyothorax-associated lymphoma, lung cancer
and MM, often manifesting with the same appearance
on imaging.
Pyothorax-associated lymphoma presents a very poor
prognosis, with a mean survival time of less than 12 months.
However, variable protocols of polychemotherapy associated
with radiotherapy may lead to higher rate of survival.
Pleural metastases
Pleural metastasis (Fig. 13) usually affect both the visceral and
parietal pleura. The most common malignancies which
metastasise to pleural metastases include: lung carcinoma, ac-
counting for up to 40 % of pleural metastases [38]; breast
carcinoma [39], commonly associated with pleural effusion,
accounts for nearly 20 % of pleural metastases; ovarian can-
cers and lymphomas (~10 %).
a bFig. 11 Unusual case of giant
solitary fibrous tumour; contrast-
enhanced CT, axial (a) and
coronal plane (b) showing a bulky
and inhomogeneous contrast-
enhancing mass of the right
hemithorax. The mediastinal
structures are compressed and
contralaterally migrated. The
hypodense areas (white arrows)
may represent the presence of
necrosis, haemorrhage or myxoid
tissue
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Rare pleural tumours
Well-differentiated papillaryMM, localisedMM, adenomatoid
tumour, epithelioid haemangioendothelioma, calcifying tu-
mour of the pleura and desmoplastic small round cell tumour
of the pleura represent only a lower percentage of all pleural
neoplasms, with not many cases described in the literature.
In all these cases the differential diagnosis among the
different histotypes is extremely difficult, especially on
small biopsy specimens, mainly because of the similar his-
topathological appearance and the similar clinical findings.
For these reasons a histological and immunohistochemical
analysis of the lesions is necessary in order to reach the
correct diagnosis.
Localised MM is histologically identical to diffuse MM in
all subtypes. Epithelioid haemangioendothelioma and well-
differentiated papillary MM may show nests of epithelioid
cells, papillary formations and fibromyxoid stroma [40].
Calcifying tumours of the pleura show collagenous and
hyalinised tissue with lymphoplasmacytic infiltrates. An
adenomatoid tumour is characterised by many eosinophilic cells
tending to form tubules and glands. Desmoplastic small round
cell tumours of the pleura typically express epithelial, mesenchy-
mal and neural cell markers, and above all a specific transloca-
tion t(11;22)(p13;q12).
In well-differentiated papillary MM and localised MM, the
correlation with asbestos exposure remains still unclear, with
just few reported cases.
These tumours are often asymptomatic, being accidentally
discovered during radiological examinations performed for other
reasons. Other common symptoms are chest pain, dyspnoea,
pleural effusion (more common in well differentiated papillary
MM, localised MM, epithelioid haemangioendothelioma and
desmoplastic small round cell tumour of the pleura), in relation
to their possible malignant behaviour, with invasion of the chest
wall, mimicking the typical symptoms of a classic MM.
Fig. 13 Pleural metastases; axial
view of unenhanced and contrast-
enhanced CT scan: lung (a), soft
tissue (b) and contrast-enhanced
image (c). A relatively small
bulky mass (arrow), that
demonstrates slightly and
homogeneous enhancement.
After analysis of the histological
specimen the lesion was found to
be a pleural metastases from
breast adenocarcinoma
a bFig. 12 Primary effusion
lymphoma; axial view contrast-
enhanced CT scan: soft tissue (a)
and lung (b) window images. A
mild pleural effusion may be seen
(arrowhead) with slightly
hyperdensity, associated with a
small lung consolidation with air
bronchogram (thick arrow); no
real pleural masses are recognised
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Well-differentiated papillary MM, adenomatoid tumours
and calcifying tumours of the pleura usually present a benign
behaviour, and their prognosis is usually good, with a
prolonged survival time.
Localised MM, epithelioid haemangioendothelioma,
desmoplastic small round cell tumour of the pleura and ad-
vanced forms of well differentiated papillary MM show an
aggressive behaviour, with both invasion of thoracic wall
structures up to the progressive encasement of the adjacent
lung parenchyma (frequent in localised MM and epithelioid
haemangioendothelioma) and widespread metastasis (more
common in desmoplastic small round cell tumour of the pleu-
ra). In these cases the prognosis is usually poor, with a mean
survival time ranging from months to a few years.
From the radiological point of view, all these forms are quite
similar and differential diagnosis is almost impossible. Accord-
ing to literature data, these tumours may appear as single or
multiple nodules, variable in dimensions (localised MM,
adenomatoid tumour, calcifying tumour of the pleura,
desmoplastic small round cell tumour of the pleura), whereas
in well-differentiated papillary MM and epithelioid
haemangioendothelioma, no real masses are detectable, and in
these two histological subtypes the pleural effusion represents
the typical radiological finding. Calcifications are typical in
calcifying tumour of the pleura and may be seen also in well-
differentiated papillary MM. Pleural thickening is common in
localised MM and epithelioid haemangioendothelioma, rare or
completely absent in the other forms [41].
In all these neoplasms, surgical resection often represents
the best therapeutic option; however, in the most aggressive
and malignant forms it cannot be suitable or sufficient, and it
can be associated with radiotherapy and chemotherapy on the
basis of different therapeutic protocols, although there is no
strong evidence in literature of the benefit of using a combi-
nation of these therapeutic options, due to the scant number of
cases and limited information.
Conclusions
MM is not the only existing pleural tumour, although it is the
most frequent. There are other histological types that can
mimic the MM by symptoms and clinical or pathological as-
pects. The knowledge of all possible existing pleural tumour
histotypes is important to perform an adequate differential
diagnosis, provide a more precise prognosis and correct man-
agement of the patient.
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